Back to results
US 8,058,316 B2Granted
STAT3 inhibiting compositions and methods
AssigneeCharlesson, LLC
InventorRafal A. Farjo
Life of this patent
Estimating the term…
Abstract
A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10 -dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration intravitreally. The composition may be administered intravitreally to a subject's eye.
Claims10
A composition comprising:
- a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of an agent having the formula:
- wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization;
- and
- wherein the composition is prepared for administration intravitreally.
1 more element
A method of treating a retinal disease in a subject, comprising:
- administering intravitreally to the subject's eye a composition comprising a pharmaceutical carrier and an amount, therapeutically effective for the treatment of the retinal disease, of an agent having the formula:
- wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization.
Dependencies are inferred from the claim text.